Merck bace inhibitor trial by fire - Prescribed Reading: Sage CEO embellishes, Merck stumbles
. . this year’s CTAD conference filled its chosen venue to fire Phase 3 trial of the BACE inhibitor Merck Pulls Plug on Phase 2/3 BACE Inhibitor
New Alzheimer’s drug studies offer patients hope. Merck Co. today announced it’s just begun the first combined mid- and late-stage study of a BACE inhibitor.
0/8/2017It has been a brutal year in the search for a treatment for Alzheimer’s — here’s where researchers are looking now. Merck discontinued one of
Jack Scott of Florida Atlantic University, Florida FAU. Read 8 publications, and contact Jack Scott on ResearchGate, the professional network for scientists.
Upcoming Alzheimer's studies may change how disease is Merck Co. announced it's just begun the first combined mid- and late-stage study of a BACE inhibitor.
Edited Transcript of MRK earnings conference call or presentation 2-May-17 our BACE inhibitor, from the first Phase III trial. I think Merck is only